Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

mwi veterinary supply, inc. - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - indicated for the treatment of arthritis caused by susceptible organisms and for mycoplasma pneumonia. lincomycin injectable is indicated for the treatment of infectious forms of arthritis caused by organisms sensitive to its activity. this includes most of the organisms responsible for the various infectious arthritides in swine, such as staphylococci, streptococci, erysipelothrix and mycoplasma spp .  it is also indicated for the treatment of mycoplasma pneumonia. as with all drugs, the use of lincomycin injectable is contraindicated in animals previously found to be hypersensitive to the drug.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

a-s medication solutions - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincomycin injection, usp is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of cdad, as described in the boxed warning , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. indicated surgical procedures should be performed in conjunction with antibacterial therapy. lincomycin injection may be administered concomitantly with other antimicrobial agents when indicated. lincomycin is not indicated in the treatment of minor bacterial infections or viral infections. to reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin and other antibacterial drugs, lincomycin should be used only to treat or prevent infections that are proven or strongly suspected

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

bracco diagnostics inc. - sincalide (unii: m03giq7z6p) (sincalide - unii:m03giq7z6p) - sincalide 5 ug in 5 ml - kinevac is indicated in adults to: - to stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals; - to stimulate pancreatic secretion in combination with secretin prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology; - to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract. kinevac is contraindicated in patients with: - a history of hypersensitivity to sulfites or sincalide. serious hypersensitivity reactions have included anaphylaxis and anaphylactic shock [see warnings and precautions (5.1), adverse reactions (6)] . - intestinal obstruction. risk summary based on limited human data and mechanism of action, sincalide may cause preterm labor or spontaneous

Australia - engleză - APVMA (Australian Pesticides and Veterinary Medicines Authority)

probus pharmaceuticals pty ltd - lincomycin as lincomycin hydrochloride - parenteral liquid/solution/suspension - lincomycin as lincomycin hydrochloride antibiotic active 300.0 mg/ml - antibiotic & related

Australia - engleză - APVMA (Australian Pesticides and Veterinary Medicines Authority)

inca (flight) co pty ltd - rotenone; sulfur-sublimed - topical dust, powder - rotenone extract-plant active 10.0 g/kg; sulfur-sublimed mineral-sulfur active 50.0 g/kg - parasiticides - calf | cat | dog | fowl | goat | horse | beef calf | billy | bitch | bovine | buck | calf - poddy | calf - preweaning | calf - s - cattle biting louse | feather lice | flea - ctenocephalides spp. | goatsucking louse | horsebiting louse | horsesucking louse | lice - bovicola spp. | lice - haematopinus spp. | mite - chorioptes bovis | mite - dermanyssus spp. | sucking louse | cattlebiting louse | chorioptic mange mite | damalinia bovis (old name) | haema spp. | werneckiella equi

Australia - engleză - APVMA (Australian Pesticides and Veterinary Medicines Authority)

inca (flight) co pty ltd - sulfaquinoxaline - oral solution/suspension - sulfaquinoxaline sulfanyl active 70.0 g/l - antibiotic & related - poultry | breeders | broiler | chickens | chicks | chooks | day old chicks | hatchlings | layers - coccidiosis | eimeria acervulina | eimeria brunetti | eimeria maxima | eimeria mivati | eimeria necatrix | eimeria tenella

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

pharmacia limited company trading as pharmacia - lincomycin hydrochloride monohydrate equivalent to 250 mg lincomycin base;   - capsule - 250 mg - active: lincomycin hydrochloride monohydrate equivalent to 250 mg lincomycin base   excipient: lactose monohydrate magnesium stearate purified talc - indicated in the treatment of upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. effectiveness in the treatment of mastoiditis would be anticipated.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

pharmacia limited company trading as pharmacia - lincomycin hydrochloride monohydrate 300 mg/ml;   - solution for injection - 300 mg/ml - active: lincomycin hydrochloride monohydrate 300 mg/ml   excipient: benzyl alcohol water for injection

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

zoetis belgium s.a. - spectinomycin; lincomycin - powder for use in drinking water - 222, 444.7 milligram(s)/gram - lincomycin, combinations - chickens, pigs - antibacterial

Australia - engleză - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - lincomycin hydrochloride monohydrate, quantity: 680.4 mg (equivalent: lincomycin, qty 600 mg) - injection, solution - excipient ingredients: benzyl alcohol; water for injections - lincomycin lws is indicated in the treatment of serious infections due to susceptible strains of gram-positive aerobes such as streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. because of the risk of colitis (see precautions), before selecting lincomycin the physician should consider the nature of infection and the suitability of less toxic alternatives (e.g. erythromycin).,lincomycin injection has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to lincomycin. staphylococcal strains resistant to lincomycin injection have been recovered; culture and susceptibility studies should be done in conjunction with lincomycin injection therapy. in the case of macrolides, partial but not complete cross resistance may occur. the drug may be administered concomitantly with other antimicrobial agents with which it is compatible when indicated (see precautions).,the specific infections for which lincomycin lws is indicated are as follows:,upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. effectiveness in the treatment of mastoiditis would be anticipated.,lower respiratory infections including acute and chronic bronchitis and pneumonia.,skin and skin structure infections including cellulitis, furuncles, abscesses, impetigo, acne and wound infections. conditions such as erysipelas, lymphadenitis, paronychia (panaritium), mastitis and cutaneous gangrene should, if caused by susceptible organisms, respond to lincomycin therapy.,bone and joint infections including osteomyelitis and septic arthritis.,septicaemia and endocarditis. selected cases of septicaemia and/or endocarditis due to susceptible organisms have responded well to lincomycin. however, bactericidal drugs are often preferred for these infections.,bacillary dysentery. although shigella is resistant to lincomycin in vitro (mic approximately 200-400 micrograms/ml), lincomycin has been effective in its treatment due to the very high levels of lincomycin attained in the bowel (approximately 3000-7000 micrograms/gram of stool).